Updated:
TEVA Pharmaceuticals
TEVA Pharmaceuticals was founded in 1901 in Jerusalem as a small wholesale drug business.
TEVA Pharmaceuticals
TEVA Pharmaceuticals was founded in 1901 in Jerusalem as a small wholesale drug business. The firm grew under the leadership of Eli Hurvitz, who served as CEO from 1976 to 2002 and later as chairman, transforming TEVA into a global generic drug powerhouse. The underlying wealth originates from TEVA's commercial success in manufacturing and distributing affordable medications worldwide. TEVA's investment strategy spans multiple asset classes including pharmaceutical R&D, manufacturing infrastructure, and strategic acquisitions. The firm targets both generic and specialty therapeutic areas, with confirmed portfolio companies including Copaxone (glatiramer acetate) for multiple sclerosis and various generic versions of blockbuster drugs. TEVA deploys capital through direct investments in internal drug development programs and manufacturing facilities across Israel, the United States, and Europe. As of 2023, TEVA employs approximately 37,000 people globally, with additional offices in the United States, Europe, Latin America, and Asia. The firm operates through TEVA Pharmaceutical Industries Ltd., the publicly traded parent company, while maintaining philanthropic structures such as the TEVA Foundation. In March 2023, TEVA announced a restructuring plan to focus on core generic and specialty drug operations (per TEVA press release, March 2023). TEVA's structural distinctiveness lies in its hybrid model — a publicly traded corporation that operates as a de facto family office for the founding families, with governance that balances commercial pharmaceutical operations against long-term wealth preservation. The founding families retain significant voting control through a dual-class share structure, a rarity among large pharmaceutical companies.
General information
Firm type
Family Office
Year founded
1901
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Petah Tiqwa
Corporate office
Petah Tiqwa, Israel
Principals
Eli Hurvitz
Former CEO and Chairman
Solomon Weksler
CEO (as of 2023)
Sector focus
Frequently asked questions
Who runs investment decisions at TEVA Pharmaceuticals?
Investment decisions at TEVA are made by the executive leadership team, including CEO Solomon Weksler and the board of directors. The firm operates as a publicly traded corporation, so capital allocation is overseen by the board with input from management. Major strategic investments require board approval, including acquisitions and R&D programs (per TEVA annual reports).
How does TEVA Pharmaceuticals source its investment opportunities?
TEVA sources opportunities through internal R&D programs, strategic acquisitions of drug candidates or companies, and partnerships with third-party research institutions. The firm has a dedicated business development team that evaluates licensing deals and acquisitions. Historically, TEVA has used large acquisitions, such as the purchase of Allergan's generic business in 2016, to expand its portfolio (per public filings).
Is TEVA Pharmaceuticals structured as a single family office, or does it operate more like a pharmaceutical company?
TEVA is primarily a publicly traded multinational pharmaceutical company, not a single family office in the traditional sense. However, its controlling families have historically managed their wealth through the corporation and related private entities. The firm's governance includes a dual-class share structure that gives founding families significant influence over corporate decisions, though day-to-day operations are run by professional management.
What investment stages does TEVA Pharmaceuticals typically target?
TEVA targets investments across the drug development lifecycle, from early-stage R&D programs to late-stage clinical trials and commercialized products. The firm also engages in strategic acquisitions of established drug portfolios. Most investments are in the generic and specialty pharmaceutical sectors, with a focus on manufacturing scale and market share rather than early-stage venture investments.
Which sectors does TEVA Pharmaceuticals explicitly avoid?
TEVA does not publicly disclose avoided sectors, but its focus remains on pharmaceuticals and related healthcare areas. The firm has not demonstrated significant activity in non-pharmaceutical sectors such as technology, real estate, or financial services. The firm's core strategy is centered on generic and specialty drug manufacturing and distribution.
How is TEVA related to the founding families' wealth?
The wealth behind TEVA originated from the founding families, including the Hurvitz family, who built the business over more than a century. The founding families hold a significant portion of TEVA's shares via a dual-class voting structure, giving them control over the corporation. This structure allows the families to manage their pharmaceutical wealth within the public company framework rather than through a separate family office entity (per public records).
Does TEVA maintain philanthropic structures, and how are they separated?
Yes, TEVA operates the TEVA Foundation, which supports healthcare access, education, and community programs in communities where TEVA operates. The foundation is funded by TEVA Pharmaceutical Industries Ltd. and is governed separately from the commercial operations. The founding families' personal philanthropic activities are managed through their own private foundations (per TEVA corporate responsibility reports).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: